Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Glioma 2Diffuse Intrinsic Pontine Glioma 2Astrocytoma 2Optic Nerve Glioma 1Oligodendroglioma 1Medulloblastoma 1Liver Cirrhosis 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Brain Stem Neoplasms 1

Interventions

Temozolomide 44Radiotherapy 20Magnetic Resonance Spectroscopy 13Irinotecan 13Carboplatin 11Bevacizumab 11Filgrastim 9Surgical Procedures, Operative 7Procarbazine 6sargramostim 5Vincristine 5Imatinib Mesylate 5Etoposide 5Erlotinib Hydrochloride 5Carmustine 5Biopsy 5etoposide phosphate 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Immunohistochemistry 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4temsirolimus 3poly ICLC 3aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Gadolinium DTPA 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligodendroglioma × Mebendazole × Clear all
NCT02644291 2022-06-23

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
16 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Brain Stem Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡